These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 37633424)

  • 21. [Potential indications of dalbavancin in clinical practice].
    Barberán J
    Enferm Infecc Microbiol Clin; 2017 Jan; 35 Suppl 1():38-40. PubMed ID: 28129820
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic Drug Monitoring of Dalbavancin Treatment in Severe Necrotizing Fasciitis in 3 Critically Ill Patients: A Grand Round.
    Corona A; Agarossi A; Veronese A; Cattaneo D; D'Avolio A
    Ther Drug Monit; 2020 Apr; 42(2):165-168. PubMed ID: 32195987
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dalbavancin: a new option for the treatment of gram-positive infections.
    Lin SW; Carver PL; DePestel DD
    Ann Pharmacother; 2006 Mar; 40(3):449-60. PubMed ID: 16507624
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dalbavancin for the management of gram-positive osteomyelitis: Effectiveness and potential utility.
    Almangour TA; Perry GK; Terriff CM; Alhifany AA; Kaye KS
    Diagn Microbiol Infect Dis; 2019 Mar; 93(3):213-218. PubMed ID: 30396697
    [TBL] [Abstract][Full Text] [Related]  

  • 25. REDS study: Retrospective effectiveness study of dalbavancin and other standard of care of the same IV antibiotic class in patients with ABSSSI.
    Papavramidis T; Gentile I; Cattelan AM; Magnasco L; Viale P; Francisci D; Kofteridis DP; Tiseo G; Giamarellos-Bourboulis EJ; Lagi F; Pinna SM; D'Amico F; La Ferla L; Panagopoulos P; Gattuso G; Sipsas NV; Ruggieri A; Cattaneo A; Corio L; Comandini A; Mascagni P; Bassetti M
    Int J Antimicrob Agents; 2023 Apr; 61(4):106746. PubMed ID: 36758778
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
    Guskey MT; Tsuji BT
    Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Pharmacokinetics and Pharmacodynamics of Dalbavancin.
    Molina KC; Miller MA; Mueller SW; Van Matre ET; Krsak M; Kiser TH
    Clin Pharmacokinet; 2022 Mar; 61(3):363-374. PubMed ID: 34931283
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dalbavancin for the management of osteomyelitis: a major step forward?
    Almangour TA; Alhifany AA
    J Antimicrob Chemother; 2020 Oct; 75(10):2717-2722. PubMed ID: 32457989
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dalbavancin: A Novel Lipoglycopeptide Antibiotic with Extended Activity Against Gram-Positive Infections.
    Smith JR; Roberts KD; Rybak MJ
    Infect Dis Ther; 2015 Sep; 4(3):245-58. PubMed ID: 26341488
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Evaluation of clinical evidence for dalbavancin].
    Rodríguez-Pardo D
    Enferm Infecc Microbiol Clin; 2017 Jan; 35 Suppl 1():33-37. PubMed ID: 28129819
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Successful Treatment of Diabetic Foot Osteomyelitis with Dalbavancin.
    Loupa CV; Lykoudi E; Meimeti E; Moisoglou I; Voyatzoglou ED; Kalantzi S; Konsta E
    Med Arch; 2020 Jun; 74(3):243-245. PubMed ID: 32801445
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative Studies.
    Dunne MW; Talbot GH; Boucher HW; Wilcox M; Puttagunta S
    Drug Saf; 2016 Feb; 39(2):147-57. PubMed ID: 26715497
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A cost-minimization analysis of dalbavancin compared to conventional therapy for the outpatient treatment of acute bacterial skin and skin-structure infections.
    Turco NJ; Kane-Gill SL; Hernandez I; Oleksiuk LM; D'Amico F; Pickering AJ
    Expert Opin Pharmacother; 2018 Mar; 19(4):319-325. PubMed ID: 29509504
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extended-duration dosing and distribution of dalbavancin into bone and articular tissue.
    Dunne MW; Puttagunta S; Sprenger CR; Rubino C; Van Wart S; Baldassarre J
    Antimicrob Agents Chemother; 2015 Apr; 59(4):1849-55. PubMed ID: 25561338
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dalbavancin for the treatment of acute bacterial skin and skin structure infections.
    Esposito S; Noviello S; Leone S
    Infez Med; 2015 Dec; 23(4):313-7. PubMed ID: 26700080
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A HPLC-DAD method to facilitate large-scale therapeutic drug monitoring of dalbavancin.
    Destere A; Merino D; Bonesso L; Lavrut T; Bernasconni A; Garraffo R; Gérard AO; Drici MD
    J Chromatogr B Analyt Technol Biomed Life Sci; 2023 May; 1222():123694. PubMed ID: 37060815
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of dalbavancin in skin and soft tissue infections.
    Bassetti M; Peghin M; Carnelutti A; Righi E
    Curr Opin Infect Dis; 2018 Apr; 31(2):141-147. PubMed ID: 29298166
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics, Safety and Tolerability of Single Dose Dalbavancin in Children 12-17 Years of Age.
    Bradley JS; Puttagunta S; Rubino CM; Blumer JL; Dunne M; Sullivan JE
    Pediatr Infect Dis J; 2015 Jul; 34(7):748-52. PubMed ID: 25551831
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The current and future off-label uses of dalbavancin: a narrative review.
    De Vito A; Fiore V; Colpani A; Zauli B; Fanelli C; Tiseo G; Occhineri S; Babudieri S; Falcone M; Madeddu G
    Eur Rev Med Pharmacol Sci; 2023 Feb; 27(3):1222-1238. PubMed ID: 36808371
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.